Marshall Wace
ARQT icon

Marshall Wace’s Arcutis Biotherapeutics ARQT Stock Holding History

Marshall Wace’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.7M Sell
446,866
-1,984,912
-82% -$46.2M 0.01% 970
2026
Q1 		$57.3M Buy
2,431,778
+1,977,545
+435% +$50.5M 0.06% 317
2025
Q4 		$13.2M Buy
454,233
+435,933
+2,382% +$11.2M 0.01% 771
2025
Q3 		$345K Buy
+18,300
New +$289K ﹤0.01% 2374
2025
Q2 		– Sell
-57,908
Closed -$906K – 2684
2025
Q1 		$906K Buy
+57,908
New +$816K ﹤0.01% 1828
2024
Q1 		– Sell
-95,011
Closed -$307K – 2419
2023
Q4 		$307K Sell
95,011
-2,216,066
-96% -$6.02M ﹤0.01% 1882
2023
Q3 		$12.3M Sell
2,311,077
-6,464
-0.3% -$55K 0.02% 581
2023
Q2 		$22.1M Buy
2,317,541
+12,205
+0.5% +$135K 0.04% 442
2023
Q1 		$25.4M Buy
+2,305,336
New +$33.4M 0.05% 378
2022
Q4 		– Sell
-167,816
Closed -$3.21M – 2914
2022
Q3 		$3.21M Buy
+167,816
New +$3.8M 0.01% 1700
2021
Q3 		– Sell
-15,138
Closed -$413K – 3000
2021
Q2 		$413K Sell
15,138
-154,349
-91% -$4.35M ﹤0.01% 2216
2021
Q1 		$4.9M Buy
169,487
+90,514
+115% +$2.83M 0.02% 855
2020
Q4 		$2.22M Buy
+78,973
New +$1.93M 0.01% 909

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Marshall Wace's ARQT Position: Q2 2026 in Review

Marshall Wace reduced its Arcutis Biotherapeutics (ARQT) stake by 82% in Q2 2026, selling an estimated $46.2M and leaving 446,866 shares worth $11.7M. The position accounts for 0.01% of the portfolio, ranked #970.

Marshall Wace first reported a position in ARQT in Q4 2020 and has held it in 13 quarters since. The position peaked at $57.3M in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Marshall Wace held 446,866 shares of Arcutis Biotherapeutics worth $11.7M as of Q2 2026.
  • Marshall Wace sold 1,984,912 Arcutis Biotherapeutics shares in Q2 2026, an estimated $46.2M.
  • Arcutis Biotherapeutics made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #970 holding.
  • Marshall Wace first reported a position in Arcutis Biotherapeutics in Q4 2020 and has held it in 13 quarters since.
  • Marshall Wace's Arcutis Biotherapeutics position peaked at $57.3M in Q1 2026.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.